JP2015504094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504094A5 JP2015504094A5 JP2014553457A JP2014553457A JP2015504094A5 JP 2015504094 A5 JP2015504094 A5 JP 2015504094A5 JP 2014553457 A JP2014553457 A JP 2014553457A JP 2014553457 A JP2014553457 A JP 2014553457A JP 2015504094 A5 JP2015504094 A5 JP 2015504094A5
- Authority
- JP
- Japan
- Prior art keywords
- sialic acid
- composition
- release formulation
- extended release
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 44
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 28
- 238000009472 formulation Methods 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 17
- 238000013265 extended release Methods 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 17
- 230000036470 plasma concentration Effects 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- 230000007812 deficiency Effects 0.000 claims description 8
- 208000013135 GNE myopathy Diseases 0.000 claims description 7
- 208000021642 Muscular disease Diseases 0.000 claims description 6
- 201000009623 Myopathy Diseases 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 239000000679 carrageenan Substances 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 229940113118 carrageenan Drugs 0.000 claims description 4
- 239000007891 compressed tablet Substances 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 3
- 229920006317 cationic polymer Polymers 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 239000000416 hydrocolloid Substances 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 235000020937 fasting conditions Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims 1
- 208000035508 distal with rimmed vacuoles myopathy Diseases 0.000 claims 1
- 238000007688 edging Methods 0.000 claims 1
- 210000003934 vacuole Anatomy 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261588069P | 2012-01-18 | 2012-01-18 | |
| US61/588,069 | 2012-01-18 | ||
| US201261709549P | 2012-10-04 | 2012-10-04 | |
| US61/709,549 | 2012-10-04 | ||
| PCT/US2013/022167 WO2013109906A2 (en) | 2012-01-18 | 2013-01-18 | Methods and formulations for treating sialic acid deficiencies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017141883A Division JP2017186381A (ja) | 2012-01-18 | 2017-07-21 | シアル酸欠乏を処置するための方法および製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015504094A JP2015504094A (ja) | 2015-02-05 |
| JP2015504094A5 true JP2015504094A5 (enrdf_load_stackoverflow) | 2015-11-12 |
Family
ID=48799814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553457A Pending JP2015504094A (ja) | 2012-01-18 | 2013-01-18 | シアル酸欠乏を処置するための方法および製剤 |
| JP2017141883A Pending JP2017186381A (ja) | 2012-01-18 | 2017-07-21 | シアル酸欠乏を処置するための方法および製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017141883A Pending JP2017186381A (ja) | 2012-01-18 | 2017-07-21 | シアル酸欠乏を処置するための方法および製剤 |
Country Status (9)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9241896B2 (en) | 2008-12-19 | 2016-01-26 | Ultragenyx Pharmaceutical Inc. | Methods and formulations for treating sialic acid deficiencies |
| CN108606956A (zh) | 2010-07-13 | 2018-10-02 | 奥特吉尼克斯制药公司 | 用于治疗唾液酸缺乏的方法和制剂 |
| CN103974965B (zh) | 2011-10-24 | 2019-09-24 | 奥特吉尼克斯制药公司 | 唾液酸类似物 |
| AR106025A1 (es) | 2015-09-14 | 2017-12-06 | Ultragenyx Pharmaceutical Inc | Formas cristalinas de ácido siálico o una sal o solvato de este |
| EP3486326A1 (en) | 2017-11-21 | 2019-05-22 | Jennewein Biotechnologie GmbH | Method for the purification of n-acetylneuraminic acid from a fermentation broth |
| CN117969774B (zh) * | 2024-04-02 | 2024-06-11 | 小仙炖霸州食品有限公司 | 一种自动化燕窝检测与分级系统 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL268475B (en) * | 2007-05-31 | 2022-08-01 | Government Of The Us Secretary Of The Department Of Health And Human Services National Institutes Of | N-acetyl mannosamine as a therapeutic agent |
| US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
| WO2010131712A1 (ja) * | 2009-05-15 | 2010-11-18 | 財団法人ヒューマンサイエンス振興財団 | Ｇｎｅタンパク質の機能低下に起因する疾患の治療用医薬剤、食品組成物、食品添加物 |
| CN108606956A (zh) * | 2010-07-13 | 2018-10-02 | 奥特吉尼克斯制药公司 | 用于治疗唾液酸缺乏的方法和制剂 |
| CN103974965B (zh) * | 2011-10-24 | 2019-09-24 | 奥特吉尼克斯制药公司 | 唾液酸类似物 |
-
2013
- 2013-01-18 JP JP2014553457A patent/JP2015504094A/ja active Pending
- 2013-01-18 KR KR1020147022912A patent/KR20150000872A/ko not_active Withdrawn
- 2013-01-18 EP EP13739040.7A patent/EP2804600A4/en not_active Withdrawn
- 2013-01-18 AU AU2013209610A patent/AU2013209610B2/en not_active Expired - Fee Related
- 2013-01-18 CA CA2862836A patent/CA2862836A1/en not_active Abandoned
- 2013-01-18 BR BR112014017587A patent/BR112014017587A8/pt not_active Application Discontinuation
- 2013-01-18 CN CN201380015020.XA patent/CN104271125A/zh active Pending
- 2013-01-18 WO PCT/US2013/022167 patent/WO2013109906A2/en active Application Filing
-
2014
- 2014-06-18 IL IL233225A patent/IL233225A0/en unknown
-
2017
- 2017-07-21 JP JP2017141883A patent/JP2017186381A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240082231A1 (en) | Niraparib formulations | |
| JP2015504094A5 (enrdf_load_stackoverflow) | ||
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| FI3902547T3 (fi) | Csf1r-inhibiittoreita käytettäväksi syövän hoitamisessa | |
| FI3562486T3 (fi) | Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa | |
| JP5918242B2 (ja) | リファキシミンを含む医薬処方物、それを得るための方法及び腸疾患を治療する方法 | |
| JP2016503030A5 (enrdf_load_stackoverflow) | ||
| EA200900264A1 (ru) | Композиции флибансерина и способ их приготовления | |
| FI3426285T3 (fi) | Pegyloidun urikaasin formulaatioita ja annoksia | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| JP2012193216A5 (enrdf_load_stackoverflow) | ||
| JP2010525050A5 (enrdf_load_stackoverflow) | ||
| WO2016210003A3 (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods | |
| MX2013001637A (es) | Composiciones farmaceuticas de liberacion controlada oral de blonanserina. | |
| JP2017507142A5 (enrdf_load_stackoverflow) | ||
| JP2017512194A5 (enrdf_load_stackoverflow) | ||
| JP2017528497A5 (enrdf_load_stackoverflow) | ||
| WO2020025742A9 (en) | Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome | |
| JP2016512247A5 (enrdf_load_stackoverflow) | ||
| JP2015531749A5 (enrdf_load_stackoverflow) | ||
| JP2016520114A5 (enrdf_load_stackoverflow) | ||
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| JP2019529572A5 (enrdf_load_stackoverflow) |